Ivana Dedinská, Ivana Ságová, Viliam Maňka, Adriana Klimentová, Pavel Makovický, Jurina Sadloňová, Marián Mokáň
Haemolytic-uraemic syndrome (or haemolytic-uraemic syndrome, abbreviated HUS) is a disease characterized by haemolytic anaemia, acute renal failure (uraemia) and a low platelet count (thrombocytopenia). Aetiologically the infection with the bacterial toxins production (pneumococcus neuraminidase, Shiga-like toxin E. coli, verotoxin shigella), medicines (hormonal contraception, cyclosporine A, mytomicyn C), tumours and others (preeclampsia, systematic lupus erythermatodes, scleroderma...) participate in its origin. The therapy is based on taking heparin, fresh plasma, corticoids, plasmapheresis and regular dialysis. Anuria persists at HUS with the presence of the Shiga-like toxin (stx-HUS) for 7 - 10 days and the kidney function fixes in 2-4 days, at HUS without the Shiga-like toxin (non Stx-HUS) anuria lasts for approximately 1 month with the subsequent fixing in 6-8 weeks. The prognosis of HUS is very good mainly at Stx-HUS. In this case the fixing of kidney function appears within 1 month in 70-80% of patients. The prognosis at non-stx-HUS is worse with the fixing of kidney function within 6-8 weeks and one third of all patients usually switch the chronic stadium of the kidney disease when the dialysis is needed.